{
    "nctId": "NCT05226871",
    "briefTitle": "Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies",
    "officialTitle": "A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED PALBOCICLIB CLINICAL STUDIES",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Head and Neck Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 35,
    "primaryOutcomeMeasure": "Number/Percentage of Participants with Treatment-Emergent Adverse Events (AEs) Leading to Permanent Discontinuation of Study Treatment and Serious Adverse Events (SAEs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Any participant who is receiving study treatment and deriving clinical benefit as determined by the investigator in a Pfizer-sponsored palbociclib Parent Study\n* Participants must agree to follow the reproductive criteria\n* Participants who are willing and able to comply with all scheduled visits, treatment plans, and other study procedures\n* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent document and protocol\n\nExclusion Criteria:\n\n* Any medical reason that, in the opinion of the investigator or sponsor, precludes the participant from inclusion in the study",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}